Endothelial-to-mesenchymal transition in multiple sclerosis: Good cells gone bad.

Neuron

Department of Neurosciences, Lerner Research Institute, Cleveland Clinic Foundation, and Case Western Reserve University, Cleveland, OH, USA. Electronic address:

Published: October 2022

In cancer and cardiovascular disease, endothelial cells can transform into mesenchymal cells (EndoMT), affecting disease onset and progression. In this issue of Neuron, Sun et al. (2022) demonstrate how EndoMT triggers breakdown of the blood-CNS barrier in the pathogenesis of multiple sclerosis.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.neuron.2022.09.017DOI Listing

Publication Analysis

Top Keywords

multiple sclerosis
8
endothelial-to-mesenchymal transition
4
transition multiple
4
sclerosis good
4
good cells
4
cells bad
4
bad cancer
4
cancer cardiovascular
4
cardiovascular disease
4
disease endothelial
4

Similar Publications

Neurodegenerative diseases are significant health concerns that have a profound impact on the quality and duration of life for millions of individuals. These diseases are characterized by pathological changes in various brain regions, specific genetic mutations associated with the disease, deposits of abnormal proteins, and the degeneration of neurological cells. As neurodegenerative disorders vary in their epidemiological characteristics and vulnerability of neurons, treatment of these diseases is usually aimed at slowing disease progression.

View Article and Find Full Text PDF

Artificial enforcement of the unfolded protein response (UPR) reduces disease features in multiple preclinical models of ALS/FTD.

Mol Ther

January 2025

Program of Cellular and Molecular Biology, Biomedical Sciences Institute (ICBM), Universidad de Chile, Santiago, Chile; Biomedical Neuroscience, Faculty of Medicine, Universidad de Chile, Santiago, Chile; FONDAP Center for Geroscience, Brain Health and Metabolism, Santiago, Chile; Buck Institute for Research on Aging, Novato, CA, USA. Electronic address:

Amyotrophic lateral sclerosis (ALS) and fronto-temporal dementia (FTD) are part of a spectrum of diseases that share several causative genes, resulting in a combinatory of motor and cognitive symptoms and abnormal protein aggregation. Multiple unbiased studies have revealed that proteostasis impairment at the level of the endoplasmic reticulum (ER) is a transversal pathogenic feature of ALS/FTD. The transcription factor XBP1s is a master regulator of the unfolded protein response (UPR), the main adaptive pathway to cope with ER stress.

View Article and Find Full Text PDF

Loss of Insight in Syndromes Associated with Frontotemporal Lobar Degeneration: Clinical and Imaging Features.

Am J Geriatr Psychiatry

December 2024

Department of Clinical and Experimental Sciences (DA, BB), University of Brescia, Brescia, Italy; Molecular Markers Laboratory (BB), IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy. Electronic address:

Objectives: The present study aims to assess the prevalence, associated clinical symptoms, longitudinal changes, and imaging correlates of Loss of Insight (LOI), which is still unexplored in syndromes associated with Frontotemporal Lobar Degeneration (FTLD).

Design: Retrospective longitudinal cohort study, from Oct 2009 to Feb 2023.

Setting: Tertiary Frontotemporal Dementia research clinic.

View Article and Find Full Text PDF

Background: Myasthenia gravis (MG) is an autoimmune disorder affecting neuromuscular junctions, leading to fluctuating muscle weakness. While many patients respond well to standard immunosuppression, a substantial subgroup faces ongoing disease activity. Emerging treatments such as complement factor C5 inhibition (C5IT) and neonatal Fc receptor (FcRn) antagonism hold promise for these patients.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!